Clinical outcomes and spatial transcriptomic profiles of CD19/20…
Nearly three-quarters of patients with hard-to-treat blood cancers responded to a new dual-targeting CAR-T therapy, with some showing benefits lasting over a year.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Semantic inductive graph-based diagnostics
A new AI model detected multiple cancer types from blood samples with over 99% accuracy, potentially enabling faster diagnosis before symptoms appear.
Underserved or high-risk populationsIntegrated Molecular Risk Stratification and Measurable Residual…
Young children with a rare blood cancer had better survival when doctors used blood tests to guide transplant timing and treatment intensity decisions.
Near-term implementable findingExpert Panel Review and Practical Guidance on Biomarker Testing With…
Cancer specialists agreed on which blood tests best predict who will struggle with CAR-T side effects, helping doctors prepare for and manage complications.
Promising but preliminarySingle-Cell RNA Sequencing Unveils CD8+ T Cell Heterogeneity in the…
Researchers mapped the immune cells that predict CAR-T success in lymphoma, revealing which cell types support remission and which mechanisms help cancers resist treatment.